Human natural killer (NK) cells have attracted widespread attention as a potential adoptive cell therapy (ACT).
However, the therapeutic effects of NK cell infusion in patients with solid tumors are limited.
There is an urgent need to explore a suitable new treatment plan to overcome weaknesses and support the superior therapeutic activity of NK cells.
